Anti-cancer antibodies with reduced complement fixation

摘要

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

主权项

1. An antibody comprising an anti-GD2 antibody variable region and an Fc region with one or more mutations decreasing complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, wherein the one or more mutations cause an absolute decrease in complement fixation, wherein the Fc region is human IgG1 and the one or more mutations include a Lys322Ala mutation within the Fc region of human IgG1.